Company Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases.
The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria.
It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases.
The company was incorporated in 2012 and is headquartered in Redwood City, California.
| Country | United States |
| IPO Date | Jul 19, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 131 |
| CEO | Dr. Robert Alexander Ph.D. |
Contact Details
Address: 975 Island Drive Redwood City, California United States | |
| Website | https://www.allakos.com |
Stock Details
| Ticker Symbol | ALLK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001564824 |
| CUSIP Number | 01671P100 |
| ISIN Number | US01671P1003 |
| Employer ID | 45-4798831 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Robert Alexander Ph.D. | Chief Executive Officer & Director |
| Baird Radford III | Chief Financial Officer |
| Alan Chang | Director of Medical Affairs & Data Analytics |
| Dr. Adam L. Tomasi Ph.D. | President |
| Dr. Chin Lee M.D., M.P.H. | Chief Medical Officer |
| Mary Cromwell Ph.D. | Chief Technical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 09, 2024 | 4 | Filing |
| Dec 09, 2024 | 4 | Filing |
| Dec 06, 2024 | 4 | Filing |
| Dec 06, 2024 | 4 | Filing |
| Nov 18, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 06, 2024 | 10-Q | Quarterly Report |
| Nov 06, 2024 | 8-K | Current Report |
| Oct 10, 2024 | 8-K | Current Report |
| Oct 10, 2024 | 8-K | Current Report |